Purpose: We aimed to develop a radiolabeled peptide probe for the imaging of hypoxia-inducible factor-1 (HIF-1)-active tumors. Procedures: We synthesized the peptide probes that contain or lack an essential sequence of the oxygen-dependent degradation of HIF-1α in proteasomes ( 123/125 I-DKOP30 or 125 I-mDKOP, respectively). The degradation of probes was evaluated in vitro using cell lysates containing proteasomes. In vivo biodistribution study, planar imaging, autoradiography, and comparison between probe accumulation and HIF-1 transcriptional activity were also performed. 
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Introduction
A n imbalance between blood supply and the rapid rate of cell growth in solid tumors creates regions of tumor hypoxia. Recently, it has been demonstrated that hypoxic tumor cells acquire active proliferating potency and enhanced metastatic characteristics and that these regions are closely related to resistance to radiotherapy and chemotherapy [1] [2] [3] . The transcription factor hypoxia-inducible factor-1 (HIF-1) is upregulated in tumor hypoxia and plays a major role in tumor progression by activating various genes related to the hypoxic response [4] . Thus, identifying HIF-1-active cells in hypoxic tumor regions can yield valuable information for appropriate cancer therapy.
HIF-1 is a heterodimer that consists of an oxygen-sensitive α subunit (HIF-1α) and the constitutively expressed β subunit (HIF-1β). HIF-1 activity is regulated mainly by degradation of the HIF-1α subunit. In normoxia, HIF-1α is hydroxylated by prolyl hydroxylases (PHDs) on the proline residues in the oxygen-dependent degradation domain (ODD). The hydroxylated proline accelerates the interaction of HIF-1α protein with von Hippel-Lindau tumor suppressor protein (pVHL), resulting in rapid ubiquitination and subsequent degradation of HIF-1α by the proteasome [5, 6] . In hypoxia, HIF-1α evades degradation and is accumulated in large amounts in the nucleus; it turns on the expression of various proteins involved in malignant progression and treatment resistance [7] . In particular, the ODD of HIF-1α is responsible for the regulation of HIF-1 activity.
It is reported that high levels of expression of HIF-1α are observed when the oxygen partial pressure (pO 2 ) drops below 40 mmHg [8] . However, different tissues have different thresholds of pO 2 for the stabilization of HIF-1α [9] [10] [11] . For example, since pulmonary cells usually exist under relatively high oxygen concentrations, the pO 2 that these cells regard as abnormal is relatively high. On the other hand, bone marrow cells are consistently exposed to low oxygen concentrations and acquire no HIF-1 activity even when they are kept under the same pO 2 as pulmonary cells [12] . Therefore, to visualize the HIF-1-active cells, probes which respond to absolute pO 2 are insufficient compared to probes which contain an ODD and are degraded in a manner similar to HIF-1α.
A chimeric protein probe (
123/125
I-IPOS) that contains an ODD and degrades in the same manner as HIF-1α under normoxic conditions was previously developed in our laboratory. A clear tumor image was obtained at 24 h after the injection of 123 I-IPOS, and accumulation of 123 I-IPOS in the tumor was found to correlate with HIF-1 activity [13] [14] [15] [16] . However, numerous criteria must be met in order to apply a protein probe to clinical use. Therefore, to expand prospective clinical application, the present study aimed to develop a peptide-based imaging probe that is degraded in a manner similar to HIF-1α. Based on the degradation mechanism of HIF-1α, we selected ODD 547-574 as the basic scaffold for the oxygen-sensitive peptide probe with modified sequences for site-specific radiolabeling and increased membrane permeability, and we evaluated the feasibility of the ODD-based peptide as an imaging probe for HIF-1-active tumor hypoxia.
Experimental Procedures

Materials
The 9-fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids and Fmoc-NH-SAL-PEG Resin were purchased from Watanabe Chemical Industries, Ltd. (Hiroshima, Japan). All of the peptides employed in this study were automatically synthesized by a peptide synthesizer (PSSM-8; Shimadzu Corporation, Kyoto, Japan). Matrix-assisted laser desorption/ ionization mass spectra (MALDI-MS) were obtained with AXIMA-CFR Plus (Shimadzu Corporation). Reverse-phase high-performance liquid chromatography (HPLC) was performed using a Shimadzu-HPLC gradient system (LC-20AD; Shimadzu Corporation) equipped with a 5C 18 -AR-II column (4.6 mm×150 mm for analytical HPLC and 10 mm× 250 mm for preparative HPLC; Nacalai Tesque, Inc., Kyoto, Japan). The analytical HPLC was carried out with a linear gradient of 0.1 % trifluoroacetic acid (TFA) in acetonitrile and 0.1 % aqueous TFA from 1:9 to 7:3 over 30 min, flow rate of 1.0 ml/min, and detection at 220 nm. Na 
Design and Synthesis of Peptides
We designed five peptides, shown in Table 1 . For sitespecific radiolabeling, a glycylcysteine was conjugated to the C-terminal of the ODD 547-574 scaffold, and the whole sequence was named OP30. To increase membrane permeability, the nine amino acids at the N-terminal of OP30 were replaced by L-lysine or D-lysine, producing the peptides KOP30 and DKOP30, respectively. Furthermore, proline residues in KOP30 and DKOP30 that were essential to oxygen-dependent degradation of the peptides were replaced by L-alanine, producing mKOP and mDKOP, respectively.
All peptides were synthesized by Fmoc-solid-phase peptide synthesis according to the standard protocol of the peptide synthesizer. N,N′-diisopropylcarbodiimide/1-hydroxybenzotriazole and N,N-diisopropylethylamine were used as coupling reagents and base, respectively. For removal of Fmoc group, 20 % piperidine in Nmethylpyrrolidone was used. Deprotection of the peptides and cleavage from the resin were simultaneously performed using TFA/ethanedithiol/H 2 
Degradation Assay of Peptide Probes
The degradation of radiolabeled peptides through the ubiquitin proteasome pathway was evaluated using a Fraction II HeLa Degradation Kit (Boston Biochem, Inc., Cambridge, MA, USA) [18] . According to the manufacturer's protocol, each peptide (75 kBq, 15 μl of 50 mM HEPES buffer, pH 7.6) was incubated with a cell extract containing proteasomes. To determine whether the degradation was proteasome dependent, a proteasome inhibitor, MG-132 (6.7 μM at final concentration), was used. After 1 h of incubation at 37°C, 50 mM HEPES buffer (100 μl) and trichloroacetic acid (30 μl) were added to stop the reaction. The reaction mixture was centrifuged at 10,000×g for 5 min at 4°C (Micro Cooling Centrifuge 1700; Kubota, Osaka, Japan), and the supernatant was filtrated using a 0.45-μm filter (Millipore; Billerica, MA, USA). The filtrate was analyzed by HPLC (analytical HPLC conditions). The eluent was collected every 1 min and radioactivity was measured with an automatic well-type γ-counter (Cobra 2; Packard Instruments, USA). The assay was performed in triplicate.
Cell Culture
HeLa human cervical carcinoma cells were obtained from the American Type Culture Collection, and FM3A mouse mammary carcinoma cells were purchased from the Health Science Research Resources Bank. Suit2/Luc human pancreatic carcinoma cells that express luciferase in response to HIF-1 activity were established by Prof. Kizaka-Kondoh [19] . All the cells were maintained in 10 % fetal bovine serum-Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical, Tokyo, Japan). The culture media were supplemented with penicillin (100 U/ml) and streptomycin (100 μg/ml). Cells were incubated at 37°C in a well-humidified incubator with 5 % CO 2 and 95 % air for normoxic culture or in an anaerobic chamber (Concept Mini MACS; Biotrace Limited, UK) for hypoxic culture (5 % CO 2 and 95 % N 2 ).
Cell Uptake Assay
HeLa cells were incubated in advance for 18 h under either normoxic or hypoxic conditions, after which 
Animal Model
Animal studies were conducted in accordance with our institutional guidelines, and the experimental procedures were approved by the Kyoto University Animal Care Committee. Female C3H/He mice and BALB/c nu/nu mice at 5 weeks of age were purchased from Japan SLC, Inc. (Hamamatsu, Japan) and kept at a constant ambient temperature under a 12-h light/ dark cycle with free access to food and water. Models of FM3A and Suit2/Luc tumors were prepared as described in previous reports [20, 21] . Approximately 2 weeks after tumor implantation, the mice were subjected to a tracer study. The average diameter of the tumors was 11 mm. The underlined letters represent D-amino acids
The mice were euthanized at 15, 60, and 120 min after injection. Whole organs were immediately collected and weighed, and the radioactivity was measured. The results were expressed as the percent injected dose per gram (% ID/g), except for the stomach and neck (%ID). The blood half-life of 125 I-DKOP30 was calculated by nonlinear regression analysis using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA) according to one-phase exponential decay.
In Vivo Planar Imaging 123 I-DKOP30 (37 MBq) was injected intravenously into FM3A-implanted mice (n=4). After 2 h, the mice were placed on a scanner bed in the supine position under 2.5 % isoflurane anesthesia. Planar images were acquired for 10 min using a SPECT-2000H scanner (Hitachi Medical Corporation, Tokyo, Japan) equipped with a low-energy, high-resolution, parallel hole collimator [13, 20 ]. An energy window was set to 160 keV±30 %. The detector used was only one-head and qualitative images were obtained. The image is shown as a raw image and is not normalized by injected radioactivity.
Autoradiography and Immunohistochemistry
Pimonidazole (PIMO, 60 mg/kg) was injected intraperitoneally into FM3A-implanted mice (n=3), and 3 h later, 125 I-DKOP30 (1.8 MBq) was injected intravenously. At 2 h after 125 I-DKOP30 injection, the tumor was removed and frozen in hexane (−80°C). The frozen tumor samples were cut into 20-μm-thick sections and adjacent 10-μm-thick sections. After 4 days of exposure of the 20-μm sections to an imaging plate (Fuji Imaging Plate BAS-SR; Fuji Photo Film, Tokyo, Japan), autoradiograms were obtained using a BAS5000 scanner (Fuji Photo Film). The adjacent 10-μm sections were subjected to dual fluorescent immunostaining for HIF-1α and PIMO according to a previously described method [21] . I-mDKOP (25 kBq) was injected intravenously into Suit2/Luc-implanted mice (n=6). D-Luciferin solution (200 μl, 10 mg/ml in saline; VivoGlo Luciferin, Promega, WI, USA) was injected intraperitoneally at 100 min after administration of the radiolabeled probe. After 20 min, the mice were anesthetized with 2.5 % isoflurane that was an optimal anesthetic because it had negligible effects on tumor hemodynamics and partial oxygen pressure [22] . Bioluminescence imaging was performed using an IVIS Spectrum System (Xenogen, Alameda, CA, USA). After the bioluminescence imaging, the mice were euthanized and the radioactivity of the tumors was measured. The bioluminescent signal intensity within the tumors was analyzed using Living Image 3.0 software (Xenogen).
Statistical Analyses
The statistical data among more than three groups were assessed by the Kruskal-Wallis test followed by a Bonferroni correction. Comparisons between two groups were performed with the Mann-Whitney U test. Correlation coefficients were assessed using the Spearman rank analysis. A P value of G0.05 was considered statistically significant.
Results
Degradation of Peptide Probes
Typical radio-HPLC chromatograms of assay samples are shown in Fig. 1 . The radiochemical purity of each probe before incubation was 995 %. After incubation with the cell extract containing proteasomes, all of the probes containing proline residues were degraded. The radioactivity eluted in the intact fraction was 5±1 % ( Moreover, the proteasome inhibitor significantly inhibited the degradation of 125 I-DKOP30 (intact fraction 75 ±6 %, PG0.01). Values are represented as the mean ± standard deviation of three examinations. I-DKOP30 under hypoxic conditions at each time point was at least 3.5-fold greater than that recorded under normoxic conditions (Fig. 2b, c) .
Cell Uptake Assay
Biodistribution
The results of the biodistribution analysis are summarized in Tables 2, 3 , and 4. The biodistribution of the three probes were similar; there was a high level of radioactivity accumulation in the kidneys and a moderate level in the blood, liver, and lung at 15 min after injection, and it fell rapidly. Radioactivity in the intestine gradually increased. Radioactivity accumulation in the neck was negligible. Compared to 125 I-KOP30, 125 I-DKOP30 and 125 I-mDKOP showed a significant greater retention by the tumor at 60 and 120 min post injection (PG0.05). Among the tumor-to-blood ratios of the three probes, only 125 I-DKOP30 was 91 at 120 min after injection, though the radioactivity accumulation in the blood and tumor was not statistically different. I-DKOP30 in the abdominal region was high, but there was little accumulation in the thoracic region, and no radioactivity accumulated in the thyroid. These findings were consistent with the data from the biodistribution evaluation.
In Vivo Planar Imaging
Autoradiography and Immunohistochemistry
The autoradiogram indicated a heterogeneous distribution of 125 I-DKOP30 in the tumor (Fig. 4) . Dual fluorescent immunohistochemistry confirmed the presence of HIF-1α-and PIMO-positive hypoxic areas in the tumor. Sections Organ uptake values are expressed as the percent injected dose per gram of tissue, except in the case of the stomach and the neck (percent injected dose).
Values are represented as the mean ± SD, n=3 Organ uptake values are expressed as the percent injected dose per gram of tissue, except in the case of the stomach and the neck (percent injected dose).
Values are represented as the mean ± SD, n=4
derived from PIMO-untreated mice were not stained with anti-PIMO antibody, and no HIF-1α signal was detected in the negative control antibody-treated sections (data not shown). Although autoradiographic images were affected by blur effect and partial volume effect, the majority of 125 I-DKOP30 accumulation was in areas that corresponded to the HIF-1α-and PIMO-positive areas (white arrowheads in Fig. 4) . However, there were also a few areas where the HIF-1α or PIMO signal was positive, but where 125 I-DKOP30 had not accumulated (black arrowheads in Fig. 4 ).
Comparison Between Probe Accumulation and HIF-1 Transcriptional Activity
There was a significant positive correlation observed between HIF-1-induced luciferase bioluminescence and 125 I-DKOP30 accumulation at 2 h after the injection (R=0.72, PG0.01; Fig. 5a ). On the other hand, tumor accumulation of 125 ImDKOP was not significantly correlated with HIF-1 transcriptional activity (R=0.35; Fig. 5b) .
Discussion
In the development of the oxygen-sensitive degradable peptide probe, it was necessary to identify a peptide sequence that would essentially be degraded in a manner similar to HIF-1α. There are three key steps in the degradation of HIF-1α: (1) hydroxylation of proline residues by PHDs; (2) pVHL binding to hydroxylated proline; and (3) ubiquitination at the lysine residue by E3 ligase with the pVHL acting as the substrate recognition component. Thus, we planned a peptide containing both proline and lysine, as well as amino acid sequences important for interaction with PHDs and pVHL, as the basic scaffold for the oxygensensitive peptide probe. There are three subtypes of PHD (PHD1-3) and two proline residues (P402 and P564) that are targeted for hydroxylation. All of the PHDs can hydroxylate P564, but only PHD1 and PHD2 can hydroxylate P402 [23] . Therefore, we thought a P564-based probe might degrade more easily than a P402-based probe. Jaakkola et al. found that ODD 556-574 was the minimal domain required for the interaction between pVHL and hydroxylated P564 [24] . In addition, three lysine residues (K532, K538, and K547) within the ODD of HIF-1α have been reported as principal ubiquitin acceptors. Only the removal of all of the lysine residues abolishes the ubiquitination of HIF-1α, whereas individual point mutations of these lysine residues had no effect on ubiquitination [25] . This finding indicates that there is no order of priority of ubiquitination in the three lysine residues. Thus, we selected ODD 547-574 as the basic scaffold for an oxygen-sensitive peptide probe and introduced a glycylcysteine for site-specific radiolabeling (OP30).
Although OP30 was actually degraded by incubation with HeLa cell lysates, this probe did not demonstrate cellular accumulation. Therefore, the ODD 547-555 region was replaced by L-or D-lysine (KOP30 or DKOP30, respectively) to increase cell membrane permeability. Both probes showed cellular accumulation as expected and were degraded by incubation with the HeLa cell lysates. On the other hand, the proline-replaced probes (mKOP and mDKOP) remained intact during the incubation with the HeLa cell lysates. Furthermore, degradation of DKOP30 was inhibited by the addition of the proteasome inhibitor. Taken together, these results indicated that the proline residue and the proteasome were required for the degradation of DKOP30, similar to HIF-1α. Interestingly, degradation was independent of the conformation of lysine residue. The low regioselectivity of E3 ligase may explain this finding, as well as previous results. For instance, Paltoglou et al. reported that the ubiquitination of HIF-1α occurred even when the lysine residue was moved several amino acids away from the original position [25] . Moreover, it has been reported that an ODD-β-galactosidase fusion protein that contains only ODD 557-574 and no lysine residue at the same original position as HIF-1α is still regulated by oxygen [26] . Several lysine residues in the fused β-galactosidase could be used as surrogate ubiquitin acceptors in the ubiquitination process.
The result of the biodistribution analysis showed high uptake and rapid clearance of I-DKOP30 and 125 I-mDKOP, the pharmacokinetics of both probes would be similar. When delivered to tumors, 125 I-DKOP30 was degraded and cleared from normoxic regions but 125 I-mDKOP was not degraded. Thus, much radioactivity could be retained in 125 I-mDKOP-treated tumor. This finding is consistent with a previous report that the clearance of point-mutated ODD probe was slower than that of nonmutated ODD probe [19] . Tumor accumulation of 125 I-DKOP30 was greater than that of 125 I-KOP30, resulting in the higher tumor-to-blood and tumor-to-muscle ratios of 125 I-DKOP30. Although the detailed reason for this phenomenon is not yet known, the finding was consistent with a previous result showing that D-forms of oligoarginines had higher tumor accumulation than L-forms [27] . One reason for this may be the difference in stability, as L-peptides are generally more susceptible than D-peptides to proteolytic enzymes that are independent of HIF-1α regulation. A significant positive correlation between probe accumulation and luciferase signal, i.e., HIF-1 transcriptional activity, was observed for 125 I-DKOP30 but not 125 I-mDKOP. The autoradiogram showed heterogeneous distribution of 125 I-DKOP30, and a majority of the 125 I-DKOP30 accumulated in areas that corresponded to HIF-1α-and PIMO-positive areas. Thus, the accumulation of 125 I-DKOP30 would reflect the expression of HIF-1. Because the expression of HIF-1 has been reported to be associated with a poor prognosis in breast, lung, and head and neck cancers [28] [29] [30] , 123 I-DKOP30 could prove useful for detecting HIF-1 activity in those tumors.
The 125 I-DKOP30 probe had better pharmacokinetics compared to 125 I-IPOS, the oxygen-sensitive degradable protein probe. Protein probes often exhibit slow clearance from the blood, which can impose a long wait to obtain a clear tumor image. I-IPOS. This may be attributed to the short period of intracellular retention of the cell penetrating peptides [31] . For further improvement of the tumor-to-blood ratio, continued modification to increase intracellular retention of 125 I-DKOP30 will be required.
There are three isoforms in the HIF-α family (HIF-1α, HIF-2α, and HIF-3α). Although HIF-3α lacks the C-terminal transactivation domain, HIF-1α and HIF-2α have 48 % amino acid sequence identity and similar protein structures. Both proteins have the ODD, and proline residues in the ODD are hydroxylated under normoxic conditions, triggering oxygen-dependent degradation of HIF-1α and HIF-2α [32] . Since 125 I-DKOP30 is a probe in principle to evaluate the enzyme activity involved in the degradation of HIF-1α as a surrogate marker of the amount of HIF-1α, it could accumulate not only in HIF-1-active but also in HIF-2-active regions. In addition that HIF-1 and HIF-2 regulate the expression of many of the same hypoxia-induced genes, each HIF also has unique target genes [4] . HIF-1 and HIF-2 play divergent but complementary roles during the hypoxic response. Although many manuscripts describe the importance of individual isoform involved in tumor, inflammation, development, etc., it is still unclear that one is more important than the other and needs to be investigated. Thus, it is yet unknown whether an isoformspecific imaging probe is required or a pan-HIF imaging probe is enough.
Conclusion
In the present study, we designed and synthesized a peptidebased imaging probe, 
